4-(2-(6-Chloroquinazolin-4-ylamino)ethyl)phenol | 1149745-63-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(2-(6-Chloroquinazolin-4-ylamino)ethyl)phenol
• 英文别名: 4-[2-[(6-chloroquinazolin-4-yl)amino]ethyl]phenol
• CAS: 1149745-63-0
• 化学式: C₁₆H₁₄ClN₃O
• 分子量: 299.76
• InChiKey: MZQYEXKXFXQJMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  58
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  对羟基苯乙胺 、 4,6-二氯喹唑啉 在 吡啶 作用下， 以 乙醇 为溶剂， 以59%的产率得到4-(2-(6-Chloroquinazolin-4-ylamino)ethyl)phenol
  参考文献：
  名称：

  Potent inhibitors of Huntingtin protein aggregation in a cell-based assay

  摘要：

  A quinazoline that decreases polyglutamine aggregate burden in a cell-based assay was identified from a high-throughput screen of a chemical-compound library, provided by the NIH Molecular Libraries Small Molecule Repository (MLSMR). A structure and activity study yielded leads with submicromolar potency. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.087

文献信息

• Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies
  申请人：THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

  公开号：US10865214B2

  公开（公告）日：2020-12-15

  The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.

  本申请公开了作为自噬通量激活剂的化合物以及包含所述激活剂的药物组合物。它进一步公开了所述化合物和药物组合物在治疗神经退行性疾病中的用途，特别是蛋白病和牛磺酸病，如阿尔茨海默病。它进一步公开了增强自噬通量的方法。
• ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES
  申请人：THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

  公开号：US20170210759A1

  公开（公告）日：2017-07-27

  The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
• [EN] ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES<br/>[FR] ACTIVATEURS DE FLUX AUTOPHAGIQUE ET DE PHOSPHOLIPASE D ET CLAIRANCE D'AGRÉGATS DE PROTÉINES COMPRENANT TAU ET TRAITEMENT DE PROTÉINOPATHIES
  申请人：UNIV COLUMBIA

  公开号：WO2017062500A2

  公开（公告）日：2017-04-13

  The present application discloses compounds which are activators of autophagic flux and pharmaceutical compositions comprising said activators. It further discloses use of said compounds and pharmaceutical compositions in the treatment of neurodegenerative diseases, particularly proteinopathies and tauopathies such as Alzheimer's disease. It further discloses methods of enhancing autophagic flux.
• Potent inhibitors of Huntingtin protein aggregation in a cell-based assay
  作者：Alison Rinderspacher、Maria Laura Cremona、Yidong Liu、Shi-Xian Deng、Yuli Xie、Gangli Gong、Nathalie Aulner、Udo Többen、Katherine Myers、Caty Chung、Monique Andersen、Dušica Vidović、Stephan Schürer、Lars Brandén、Ai Yamamoto、Donald W. Landry

  DOI：10.1016/j.bmcl.2009.01.087

  日期：2009.3

  A quinazoline that decreases polyglutamine aggregate burden in a cell-based assay was identified from a high-throughput screen of a chemical-compound library, provided by the NIH Molecular Libraries Small Molecule Repository (MLSMR). A structure and activity study yielded leads with submicromolar potency. (C) 2009 Elsevier Ltd. All rights reserved.